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ABSTRACT
Purpose Resistance to chemotherapy is one of the major
problems facing current cancer research. Enhancing tumor
cell response to anticancer agents increases chemotherapeutic
effectiveness. We have recently addressed this issue and re-
ported on producing multifunctional nanoparticles
(Fe3O4@SiO2(FITC)-FA/AICAR/DOX) aiming to over-
come chemoresistance with synergetic effect of AICAR and
DOX. In the present study, we demonstrated that these nano-
particles not only show enhanced cellular uptake and cytotox-
ic effect but can also show enhanced pro-apoptotic and anti-
proliferative effects in five different tumor-derived cell lines
(A549, HCT-116, HeLa, Jurkat and MIA PaCa-2).
Methods The nanoparticles were examined by using flow
cytometric analyses of apoptosis and cell cycle. In addition,
we performed caspase-3 activity assay, which supported our
flow cytometric data. Furthermore, we demonstrated the ap-
plicability of this approach in a variety of cancer types
confirming the potential widespread utility of this approach.
Results With the concept of co-delivery of AICAR and DOX
in the nanoparticle formulation, the use of AICAR against
survivin (BIRC5) sensitized cancer cells to DOX chemotherapy
which resulted in effective cancer cell elimination. These result
showed that combination therapy involving both a molecular-
ly targeted therapy and chemotherapeutic agent has the abil-
ity to retain and enhance therapeutic efficacy.
Conclusion Fe3O4@SiO2(FITC)-FA/AICAR/DOX nano-
particles is superior to monotherapy via the synergetic effect
of AICAR and DOX and also the nanoparticle formulation
could overcome issues of toxicity with targeted therapy while
maintaining the potent anticancer effects of AICAR and
DOX.
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ABBREVIATIONS
7-ADD 7-aminoactinomycin
AICAR 5-aminoimidazole-4-carboxamide-1-β-D-
ribofuranoside
APTES 3-aminopropyltriethoxysilane
DMEM Dulbecco’s modified Eagle medium
DOX Doxorubicin
FA Folic acid
FACS Fluorescence-activated cell sorting
FBS Fetal bovine serum
FITC Fluorescein isothiocyanate
Hsp90 Heat shock protein 90
IAPs Inhibitors of apoptosis proteins
PBS Phosphate buffered saline
PE-annexin-V Phycoerythrin-annexin-V
PI Propidium iodide
RPMI-1640 Roswell Park Memorial Institute-
1640 medium
INTRODUCTION
A characteristic feature of human cancers is the lack of a
proper apoptotic response upon treatment with chemothera-
peutic agents (1). Therefore, evasion of apoptosis constitutes a
critical cause of drug resistance that frequently occurs in var-
ious human cancers. Cancer cells are typically subject to a
fairly small number of antiapoptotic proteins for their survival,
* Cenk Daglioglu
cenkdaglioglu@iyte.edu.tr
1 Faculty of Science, Department of Molecular Biology and Genetics, Izmir
Institute of Technology, Urla/Izmir 35430, Turkey
2 Faculty of Science, Biochemistry Department, Ege University, Bornova/
Izmir 35040, Turkey
Pharm Res (2017) 34:175–184
DOI 10.1007/s11095-016-2053-7
(2) thus providing a strong reason for targeting these proteins
therapeutically. Inhibitors of apoptosis proteins (IAPs) are a
family of endogenous antiapoptotic proteins which play criti-
cal roles in suppression of apoptosis. High expression of IAPs
in cancer cells has been shown to interfere with the efficacy of
chemotherapy by activating the antiapoptotic program which
produces resistance to chemotherapeutic agents (3). Thus, the
inhibition of IAP members offers a novel perspective in the
struggle against drug resistance. Survivin, a structurally
unique member of the IAP family that acts as a suppressor
of apoptosis and plays a central role in cell division, is rarely
expressed in normal healthy tissues but upregulated in all hu-
man cancers (4). Because of this upregulation in malignancy
and its functional involvement in apoptosis and proliferation,
survivin is currently attracting considerable interest both as a
potential cancer biomarker (5) and as a new molecular target
for cancer treatment (6). Multiple studies showed that high
levels of survivin in tumor cells confer resistance to a range
of anticancer drugs (7). Indeed, in many of these reports,
blocking or neutralizing the actions of survivin was found to
enhance the response to multiple types of conventional cancer
therapies (8).
As survivin is not a cell surface protein and does not have
an intrinsic enzymatic activity, targeting of survivin for thera-
peutic purposes might be expected to be difficult. In addition,
crystallographic data has revealed few potential drugable sites
on survivin protein (9). Despite these problems, a multiplicity
of strategies has been employed to target the expression/
function of survivin at the transcriptional or post-
translational levels (10). One of the important targets in these
strategies is the heat shock protein 90 (Hsp90), a molecular
chaperone that oversees the correct conformational develop-
ment of polypeptides and protein refolding through sequential
ATPase cycles and stepwise recruitment of co-chaperones.
This adaptive pathway is extensively exploited in cancer,
where Hsp90 ATPase activity is upregulated approximately
100-fold (11). A physical interaction between the Hsp90
ATPase domain and the survivin BIR domain, has been
shown to be essential for the stability and function of survivin
(12). Thus, targeting the survivin-Hsp90 complex provides a
strategy to simultaneously disable multiple signaling pathways
in tumors. This interaction structurally inhibited the chaper-
one activity and exhibited potent and selective anticancer ac-
tivity in preclinical models by using an antibiotic derivative of
17-AAG and a peptidomimetic antagonist of shepherdin (13).
More recently, Meli et al. used shepherdin as a scaffold to
rationally identify low-molecular-weight compounds that
may act as structurally novel Hsp90 inhibitors. They first re-
ported that the non-pept id ic smal l molecule 5-
aminoimidazole-4-carboxamide-1-β-D-ribofuranoside
(AICAR) binds the Hsp90 N-terminal domain, mimicking the
chemical and conformational properties of shepherdin.
AICAR has been shown to destabilize several Hsp90 client
proteins in vivo, including survivin, and to exhibit antiprolifer-
ative and proapoptotic activity in multiple tumor cell lines,
while not affecting proliferation of an immortalized human
fibroblast cell line (14).
Doxorubicin (DOX) is a common chemotherapeutic used
in the treatment of a wide range of cancers because of its
excellent anti-tumor activity (15). Resistance to this agent im-
pairs treatment of cancer patients and is an obstacle to suc-
cessful treatment (16). In addition, DOX has a relatively low
therapeutic index and its clinical usage is limited due to acute
and chronic toxicities such as immunosupression and
cardiotoxicity (17). Therefore, more efficient treatment strat-
egies must be developed that reduce or eliminate drug resis-
tance, decrease the cytotoxic effects of DOX and also enhance
therapeutic efficacy. To address this problem, we have previ-
ously established a multifunctional nanoparticle platform
(Fe3O4@SiO2(FITC)-FA/AICAR/DOX) and demonstrated
its capability in cellular uptake and cytotoxic effect in five
different tumor-derived cell lines (A549, HCT-116, HeLa,
Jurkat and MIA PaCa-2) (18).
In the present study, we took the application of this plat-
form to the next step and investigated its proapoptotic and cell
proliferation inhibition effects in the same cancer cell lines
with its four different forms to evaluate the synergistic poten-
tial of therapeutics separately: (1) Fe3O4@SiO2(FITC)-FA
nanoparticles without any inhibitor or drug used as control;
(2) Fe3O4@SiO2(FITC)-FA/AICAR nanoparticles contain-
ing only inhibitor; (3) Fe3O4@SiO2(FITC)-FA/DOX nano-
particles containing only drug; (4) Fe3O4@SiO2(FITC)-FA/
AICAR/DOX nanoparticles containing both inhibitor and
drug. We examined these platforms by using flow cytometric
analyses of apoptosis with 7-ADD/PE-annexin-V double
staining and cell cycle with propidium iodide DNA staining.
In addition, we performed caspase-3 activity assay to reveal
activation levels of caspase-3 in apoptosis, supporting our flow
cytometric data. Furthermore, We used tumor-derived cell
Fig. 1 Apoptosis analysis of A549, HCT-116, HeLa, Jurkat and MIA PaCa-2
cells by flow cytometry. (a) PE-annexin-V / 7-ADD double staining of cancer
cells treated with 10 μg/ml concentration of (1) Fe3O4@SiO2(FITC)-FA (2)
Fe3O4@SiO2(FITC)-FA/AICAR, (3) Fe3O4@SiO2(FITC)-FA/DOX or (4)
Fe3O4@SiO2(FITC)-FA/AICAR/DOX nanoparticles. Viable cells labelled with
PE-annexin-V(-)/7-ADD(-), early apoptotic cells labelled with PE-annexin-V(+
)/7-ADD(-) and apoptotic cells labelled with PE-annexin-V(+)/ 7-ADD(+) in
flow cytometric graphics. (b) The percent of double positive cells in A549,
HCT-116, HeLa, Jurkat and MIA PaCa-2 cells treated with the nanoparticles.
Non-treated cells were used as control. Each column represents the mean±
SD of three independent experiments performed in triplicate (n= 3).
Immobilization concentration of: AICAR on Fe3O4@SiO2(FITC)-FA/AICAR
nanopa r t i c l e s i s 6 .1 μM per mg nanopa r t i c l e s ; DOX on
Fe3O4@SiO2(FITC)-FA/DOX nanoparticles is 1.0 μM per mg nanoparticles;
AICAR and DOX on Fe3O4@SiO2(FITC)-FA/AICAR/DOX nanoparticles are
4.5 μM and 0.7 μM per mg nanoparticles respectively. Note that the amount
of DOX conjugation on the surface of Fe3O4@SiO2(FITC)-FA/AICAR/DOX
nanoparticles is 30% less than the surface of Fe3O4@SiO2(FITC)-FA/DOX
nanoparticles.
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lines with native differences in their biochemical profile as
diverse as lung, colon colorectal, cervix, pancreatic carcinoma
and acute T-cell leukemia, to investigate the cell-type specific
impact of the nanoparticles and thus to demonstrate the ap-
plicability of this approach in a variety of cancer types
confirming the potential widespread utility of this approach.
MATERIAL AND METHODS
Materials
Propidium iodide (PI), RNase A and trypsin were purchased
from Sigma-Aldrich Chemicals. DMEM growth medium, RPMI-
1640 growth medium, 10% Fetal bovine serum (FBS), strep-
tomycin, penicillin and L-glutamic acid were purchased from
Gibco Life technologies. BCA protein assay kit was purchased
from Thermo Fisher Scientific. 7-aminoactinomycin (7-ADD)
and PE-annexin-V were purchased from BD Biosciences.
Caspase-3 colorimetric assay kit was purchased from
BioVision, Inc (USA). All other chemicals and reagents were of
the highest purity. All experiments were performed with de-
ionized Milli-Q water.
Cell Cultures
A549 (human epithelial lung carcinoma), HCT-116 (human
epithelial colorectal carcinoma), HeLa (human epithelial cer-
vical carcinoma), Jurkat (human acute T-cell leukemia) and
MIA PaCa-2 (human epithelial pancreatic carcinoma) cell
l ines were kindly provided by Biotechnology and
Bioengineering Research and Application Centre, Izmir
Institute of Technology, Turkey. A549, HCT-116, HeLa
and MIA PaCa-2 cancer cells were cultured in Dulbecco’s
modified Eagle medium (DMEM) supplemented with 10%
fetal bovine serum (FBS), 100 μg/ml streptomycin, 100
U/ml penicillin and 2mML-glutamic acid. Jurkat cancer cells
were cultured in Roswell Park Memorial Institute-1640
(RPMI-1640) growth medium supplemented with 10% fetal
bovine serum (FBS), 100 μg/ml streptomycin, 100 U/ml pen-
icillin and 2 mML-glutamic acid. All cell lines were incubated
in 5%CO2 and 90–100% relative humidity at 37°C.Medium
renewal was carried out 2 to 3 times per week, and cells were
subcultured when they achieved 80–90% confluence. All cell
lines were discarded after 20 generations, and new lines were
obtained from frozen stocks.
Nanoparticles Synthesis and Characterization
The Fe3O4@SiO2(FITC)-FA/AICAR/DOX nanoparticles
were synthesized in our previous work as described in Ref.
18. Briefly, Fe3O4 nanocrystals were synthesized by a simple
Fig. 1 continued.
Fig. 2 Apoptosis analysis of A549, HCT-116, HeLa, Jurkat and MIA PaCa-2
cells by flow cytometry. (a) PE-annexin-V / 7-ADD double staining of cancer
cells treated with 50 μg/ml concentration of (1) Fe3O4@SiO2(FITC)-FA (2)
Fe3O4@SiO2(FITC)-FA/AICAR, (3) Fe3O4@SiO2(FITC)-FA/DOX or (4)
Fe3O4@SiO2(FITC)-FA/AICAR/DOX nanoparticles. Viable cells labelled with
PE-annexin-V(-)/7-ADD(-), early apoptotic cells labelled with PE-annexin-V(+
)/7-ADD(-) and apoptotic cells labelled with PE-annexin-V(+)/ 7-ADD(+) in
flow cytometric graphics. (b) The percent of double positive cells in A549,
HCT-116, HeLa, Jurkat and MIA PaCa-2 cells treated with the nanoparticles.
Non-treated cells were used as control. Each column represents the mean±
SD of three independent experiments performed in triplicate (n= 3).
Immobilization concentration of: AICAR on Fe3O4@SiO2(FITC)-FA/AICAR
nanopa r t i c l e s i s 6 .1 μM per mg nanopa r t i c l e s ; DOX on
Fe3O4@SiO2(FITC)-FA/DOX nanoparticles is 1.0 μM per mg nanoparticles;
AICAR and DOX on Fe3O4@SiO2(FITC)-FA/AICAR/DOX nanoparticles are
4.5 μM and 0.7 μM per mg nanoparticles respectively. Note that the amount
of DOX conjugation on the surface of Fe3O4@SiO2(FITC)-FA/AICAR/DOX
nanoparticles is 30% less than the surface of Fe3O4@SiO2(FITC)-FA/DOX
nanoparticles.
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co-precipitation of Fe+2/Fe+3 salts and then microemulsion
sol–gel chemistry was used to construct layers of silica shells
for colloidal protection, dye-doping and molecular
functionalization. In this step, fluorescent dye (FITC) was
chemically encapsulated into the silica shell to enhance pho-
tochemical stability and to protect the dye leaching into the
reaction medium under harsh conditions. FA molecules were
then covalently immobilized on Fe3O4@SiO2(FITC) struc-
ture by e s t e r i f i ca t ion and media t ion o f the 3-
aminopropyltriethoxysilane (APTES) to specific and efficient
delivery of nanoparticles into cancer cells. Lastly, amine mod-
ified Fe3O4@SiO2(FITC)-FA/NH2 structure was furnished
with AICAR and DOX complexes by Schiff-base formation
to combine therapeutic functionalities in a single platform.
The structure of the newly synthesized nanoparticles was
confirmed by different physicochemical characterization tech-
niques: dynamic light scattering (DLS), X-ray diffraction
(XRD), Fourier transform infrared spectroscopy (FT-IR),
thermogravimetric analysis (TGA), energy-dispersive X-ray
spectroscopy (EDX) and scanning/transmission electron mi-
croscopy (SEM and STEM). Additionally, the feasibility of
nanoparticles was first evaluated by investigating their capa-
bility in cellular uptake, fluorescent imaging and cytotoxic
effect in five different tumor-derived cell lines (A549, HCT-
116, HeLa, Jurkat and MIA PaCa-2).
Detection of Apoptotic Cells by Flow Cytometry
The percentage of cells undergoing apoptosis induced by
nanoparticles was measured using flow cytometry with 7-
ADD and PE-annexin-V double staining. A549, HCT-
116, HeLa, Jurkat and MIA PaCa-2 cells (1 × 105 cells/
well) were seeded in 6-well plates with 2 ml of medium
overnight before experiments. (1) Fe3O4@SiO2(FITC)-FA
Fig. 2 continued.
Fig. 3 Effects of (1)
Fe3O4@SiO2(FITC)-FA (2)
Fe3O4@SiO2(FITC)-FA/AICAR, (3)
Fe3O4@SiO2(FITC)-FA/DOX or
(4) Fe3O4@SiO2(FITC)-FA/AICAR/
DOX nanoparticles on caspase-3
activation of A549, HCT-116,
HeLa, Jurkat and MIA PaCa-2 cells.
Caspase-3 activity was measured in
cell lysates after 48 h incubation by
hydrolysis of fluorogenic substrate
N-acetyl-Asp-Glu-Val-Asp-pNA
(DEVD-pNA). Each column
represents the mean values (±SD)
of three independent experiments
(n=3, Student’s t test, *p<0.001)
normalized to non-treated cells
(taken as 100%).
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( 2 ) F e 3 O 4 @ S i O 2 ( F I T C ) - F A / A I C A R , ( 3 )
F e 3 O 4 @ S i O 2 ( F I T C ) - F A / D O X o r ( 4 )
Fe3O4@SiO2(FITC)-FA/AICAR/DOX nanoparticles
were added into the incubation medium separately at 10
or 50 μg/ml concentrations and then the cells were incu-
bated for 4 h to allow uptake of the nanoparticles in 5%
CO2 at 37°C. Before analysis, the cells were carefully
washed with cold PBS, digested with trypsin (except
Jurkat) and collected by centrifugation. The cells were
washed twice with cold PBS, resuspended in 200 μl of
annexin binding buffer and stained with 10 μl of 7-ADD
and PE-annexin-V. The stained cells were first incubated
for 15 min. at room temperature by protecting from light,
and then analyzed by flow cytometry. The untreated cells
incubated with medium alone were used as the controls.
Unstained cells, cells stained with PE-annexin-V alone
and cells stained with 7-AAD alone were used to set up
compensation and quadrants. Flow cytometric analysis
was per formed on a FACS (Facscanto ; Becton
Dickinson, San Jose, CA) by counting 10,000 events.
Caspase-3 Catalytic Activity Assay
Changes in caspase-3 enzyme activity of the cells are an im-
portant sign of apoptosis. To assess the effect of combination
therapy on cell death, caspase-3 activity was analyzed
fluorometrically by means of the Caspase-3/CPP32 colori-
metric assay kit according to the manufacturer’s instructions
(BioVision Inc, USA). For this purpose, A549, HCT-116,
HeLa, Jurkat and MIA PaCa-2 cells (5 x 105 cells/well) were
incubated with 50 μg/ml concentrations of nanoparticles for
48 h at 37°C under 5% CO2. This method is based on the
hydrolysis of the peptide substrate acetyl-Asp-Glu-Val-Asp p-
nitroanilide (DEVD-pNA) by caspase-3, resulting in the re-
lease of the p-nitroaniline moiety. p-Nitroaniline was mea-
sured at 405 nm using plate reader.
Cell Cycle Analysis by Flow Cytometry
To determine the antiprol i ferat ive ef fects of (1 )
Fe3O4@SiO2(FITC)-FA (2) Fe3O4@SiO2(FITC)-FA/
AICAR, (3) Fe3O4@SiO2(FITC)-FA/DOX or (4)
Fe3O4@SiO2(FITC)-FA/AICAR/DOX nanoparticles
against A549, HCT-116, HeLa, Jurkat and MIA PaCa-2
cells, cell cycle distributions were analyzed by flow
cytometry-based propidium iodide (PI) staining. The cells
(1 × 105 cells/well) were seeded in 6-well plates with 2 ml of
medium overnight before experiments and then incubated
with 50 μg/ml concentrations of nanoparticles for 24 h at
37°C under 5% CO2. After the incubation, the cells were
trypsinized, washed once with PBS and fixed in 80% ethanol
overnight at -20°C. The next day, after centrifugation of fixed
cells, the pellet washed with cold PBS and then resuspended in
DNA staining solution [200 μl 0.1% Triton X-100 in PBS,
20 μl (200μg/ml) RNase A and 20 μl (1mg/ml) propidium
iodide] for 30 min at room temperature. The stained cells
were analyzed using flow cytometer. The fraction of the G0-
G1, S and G2-M phase of cells on DNA histograms was an-
alyzed by ModFit software.
Statistical Analysis
All data were represented as means ± standard deviation (SD)
for triplicate experiments. Statistical analysis was performed
with the Student’s t test, using Excel Software (Microsoft). A P
value of ≤0.05 was considered statistically significant.
RESULTS AND DISCUSSION
Detection of Apoptotic Cells by Flow Cytometry
We investigated the impact of survivin inhibition with
AICAR on DOX sensitivity by comparing apoptotic ef-
fects of the nanoparticles with both low-dose and IC50
concentrations (10 / 50 μg/ml) against A549, HCT-116,
H e L a , J u r k a t a n d M I A P a C a - 2 c e l l s .
Fe3O4@SiO2(FITC)-FA/AICAR/DOX nanoparticles,
versus the other nanoparticles at low-dose (10 μg/ml) con-
centration, strongly increased the percent of double (PE-
annexin-V/ 7-ADD) positive apoptotic cells in A549 and
HeLa cells to 59.1 and 51.9% while lower effects were
observed in HCT-116, Jurkat and MIA PaCa-2 cells with
the percents of 28.0 / 6.3 / 15.2%, respectively (Fig. 1).
When 50 μg/ml concentration of the nanoparticle was
applied to the cells, nearly no viability was observed in
A549, HeLa and Jurkat cells while 25% of HCT-116 and
31% of MIA PaCa-2 cells were determined as viable
(Fig. 2). Fe3O4@SiO2(FITC)-FA/DOX nanoparticles did
not significantly increase apoptotic cell death compared to
Fe3O4@SiO2 (FITC) -FA/AICAR nanopar t i c l e s .
Interestingly, treatment with nanoparticles conjugated
with AICAR alone showed considerable apoptotic effect,
confirming AICAR’s functional involvement in apoptosis.
Furthermore, we observed the induction of consi-
derable leve l s o f dose-dependent necros i s wi th
Fe3O4@SiO2(FITC)-FA control nanoparticles in all cells,
indicating that FA-linked nanocarriers successfully pene-
trated into the cells via folate-receptor mediation and
caused necrotic (passive) cell death with accumulation of
the vectors into the cancer cells. Overall, these results
suggested that nanoparticles conjugated with DOX alone
induced apoptosis in the cell. However, it also caused
upregulation of survivin, lowering the level of apoptosis.
The depletion of survivin by AICAR abolished this anti-
apoptotic effect and resulted in the most improved
AICAR and DOX Conjugated Multifunctional Nanoparticles 181
apoptotic rates in all cells with the synergistic effect of
DOX. These results corroborated that survivin plays an
important role in the drug-resistant phenotype of human
cancer cells. Zaffaroni et al. reported that stable transfec-
tion of human ovarian cancer cell lines with survivin
cDNA was able to protect them from the cytotoxic effects
induced by taxol and taxotere (19). An increase in survivin
expression has also been reported in colorectal cancer
cells resistant to TNF-related apoptosis inducing ligand
(TRAIL) (20). Asanuma et al. first reported that survivin
acts as a constitutive radioresistance factor in pancreatic
cancer cells (21). Olie et al. showed that anti-sense
targeting of survivin sensitizes lung cancer cells to
e t o p o s i d e c h e m o t h e r a p y . ( 2 2 ) B r i e f l y ,
Fe3O4@SiO2(FITC)-FA/AICAR/DOX nanoparticles
clearly advanced survivin neutralization resulting in an
increased level of anticancer activity of apoptosis-
inducing agent in five different tumor derived cell lines.
Thus, this work confirms the potential widespread utility
of these multipurpose nanoparticles.
Caspase-3 Catalytic Activity Analysis
To determine the apoptotic effects of the nanoparticles on
A549, HCT-116, HeLa, Jurkat and MIA PaCa-2 cells, the
cells were also evaluated bymeasuring caspase-3 activity, since
caspase-3 is a crucial component of apoptotic cell death.
These cells were incubated with 50 μg/ml concentration of
the nanoparticles for 48 h and changes in caspase-3 enzyme
activities were analyzed. Incubation of A549 cells with
Fe3O4@SiO2(FITC)-FA/AICAR/DOX nanoparticles dem-
onstrated significant (p< 0.001) induction of caspase-3 activity
(150%) when compared with untreated cells. Consistent with
this result, we also found 70% / 100% / 100% / %50 in-
creases in caspase-3 activity in response to 48 h incubation on
HCT-116, HeLa, Jurkat and MIA PaCa-2 cells, respectively
(Fig. 3). On the other hand, we observed no increases in
ca spa s e -3 ac t i v i t y i n the ce l l s i n cuba t ed w i th
Fe3O4@SiO2(FITC)-FA control nanoparticles confirming
the necrotic cell death obtained by flow cytometry. The results
revealed that Fe3O4@SiO2(FITC)-FA/AICAR/DOX nano-
particles led to the highest activation of caspase-3 in the lung
carcinoma A549 cell line, while also promoted the activation
of caspase-3 on the colon carcinoma HCT-116, cervical car-
cinoma HeLa, the leukemia Jurkat, and the pancreatic carci-
noma MIA PaCa-2 cell lines, which supports the anti-tumor
effect of the nanoparticles for wide range of cancer types.
Cell Cycle Analysis by Flow Cytometry
One critical point of our study was to investigate differences in
the proliferation of cancer cells following the nanoparticles
incubation, with the expectation that synergistic inhibition of
the cells would promote the anti-proliferative effect. All of the
cell lines treated with Fe3O4@SiO2(FITC)-FA/AICAR/
DOX and Fe3O4@SiO2(FITC)-FA/DOX nanoparticles sig-
nificantly depressed cell proliferation at the G2/M phase
(Fig. 4). Fe3O4@SiO2(FITC)-FA/AICAR/DOX nanoparti-
cles arrested more cells, especially in A549 and Jurkat cells
at the G2/M phase compared with Fe3O4@SiO2(FITC)-
FA /DOX n a n o p a r t i c l e s . T h i s i m p l i e d t h a t
Fe3O4@SiO2(FITC)-FA/AICAR/DOX nanoparticles have
more cell cycle arrest capacity as compared with
Fe3O4@SiO2(FITC)-FA/DOX nanoparticles. Consistent
with these results, it has been suggested that survivin expres-
sion is predominantly regulated by a cell cycle dependent and
cell cycle homology region within the promoter, which leads
to maximum expression during the G2/M phase of the cell
cycle (23). Li et al. showed that cells transfected with a mutant
survivin gene or survivin anti-sense appeared to show in-
creased caspase-3 activity when synchronized in G2/M phase
(24). The cell cycle distribution of the cells exposed to
Fe3O4@SiO2(FITC)-FA/AICAR nanoparticles was found
to be similar with the cells exposed to Fe3O4@SiO2(FITC)-
FA control nanoparticles and untreated cells. On the basis of
these findings, we hypothesized that the concentration of
Fe3O4@SiO2(FITC)-FA/AICAR nanoparticles was not suffi-
cient alone to affect cell cycle arrest as seen in viability test in
our previous work (18). Alternatively, there is a slight possibil-
ity that these nanoparticles induce apoptosis without cell cycle
arrest.
CONCLUSION
The aim of this study was to test novel Fe3O4@SiO2(FITC)-
FA/AICAR/DOXmultifunctional nanoparticles for neutral-
izing survivin with AICAR to potentiate the efficacy of DOX
for targeted cancer therapy. We analyzed the impact of
Fe3O4@SiO2(FITC)-FA/AICAR/DOX nanoparticle treat-
ments by comparing the nanoparticles conjugated with
DOX or AICAR alone against the Fe3O4@SiO2(FITC)-FA
control nanoparticles. In this study, we also used tumor-
derived cell lines with native differences in their biochemical
Fig. 4 Effect of 1) Fe3O4@SiO2(FITC)-FA (2) Fe3O4@SiO2(FITC)-FA/
AICAR, (3) Fe3O4@SiO2(FITC)-FA/DOX or (4) Fe3O4@SiO2(FITC)-FA/
AICAR/DOX nanoparticles on the cell cycle distribution of A549, HCT-116,
HeLa, Jurkat and MIA PaCa-2 cells determined by flow cytometry-based PI
staining. Immobilization concentration of: AICAR on Fe3O4@SiO2(FITC)-FA/
AICAR nanoparticles is 6.1 μM per mg nanoparticles; DOX on
Fe3O4@SiO2(FITC)-FA/DOX nanoparticles is 1.0 μM per mg nanoparticles;
AICAR and DOX on Fe3O4@SiO2(FITC)-FA/AICAR/DOX nanoparticles are
4.5 μM and 0.7 μM per mg nanoparticles respectively. Note that the amount
of DOX conjugation on the surface of Fe3O4@SiO2(FITC)-FA/AICAR/DOX
nanoparticles is 30% less than the surface of Fe3O4@SiO2(FITC)-FA/DOX
nanoparticles.
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profile to investigate the potential widespread utility of the
nanoparticles. It was found that the Fe3O4@SiO2(FITC)-
FA/AICAR/DOX nanoparticles significantly improved apo-
ptosis rate while inhibiting cell proliferation of five different
cancer cell lines. Our data indicate strong proapoptotic and
antiproliferative effects of Fe3O4@SiO2(FITC)-FA/AICAR/
DOX nanoparticles on the lung carcinoma cell line A549.
The nanoparticles showed high proapoptotic effects at low-
dose concentrations on the cervical carcinoma HeLa and the
colon carcinoma HCT-116 cells, and at IC50 concentration
on the leukemia Jurkat and the pancreatic carcinoma MIA
PaCa-2 cells, is consistent with previous study (25) that have
demonstrated that resistance to chemotherapy correlates with
expression levels of survivin in different tumor types, with the
highest levels of expression in lung cancer lines followed by
ovarian, colon and leukemia. We additionally assessed
caspase-3 activity to reveal activation levels of caspase-3 in
apoptosis, which supported our flow cytometric data.
Furthermore, the cell cycle distribution of cell lines showed
that the nanoparticles arrest all cells in the G2/M phase
confirming increased cell proliferation inhibition at the G2/
M checkpoint. Moreover, Fe3O4@SiO2(FITC)-FA/AICAR/
DOX nanoparticles led to approximately a 30% decrease in
the use of DOX in Fe3O4@SiO2(FITC)-FA/DOX nanopar-
ticles, a reduction that is significant in a clinical context. These
observations suggest that combination therapy with
Fe3O4@SiO2(FITC)-FA/AICAR/DOX nanoparticles is not
only superior to monotherapy via the synergetic effect of
AICAR and DOX but also the nanoparticle formulation
could overcome issues of toxicity while maintaining the potent
anticancer effects of AICAR and DOX. However, further
in vivo evaluation needs to be done to characterize more pre-
cisely the synergetic effect of AICAR andDOX in the concept
of nanoparticle delivery system.
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